Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
News

Tay-Sachs Drug Trial Yields ‘Neutral’ Results

Two clinical studies for the treatment of late-onset Tay-Sachs with Zavesca, a drug used to treat Gaucher disease, produced neutral results — “a scientific way of saying that it didn’t work,” said Kim Crawford, director of member services for the National Tay-Sachs & Allied Diseases Association.

According to Crawford, Actelion, which produces Zavesca, will not seek FDA approval for the drug’s use on late-onset Tay-Sachs. Tay-Sachs is a lysosomal storage disorder that involves insufficient activity of the hexosaminidase A enzyme. Both Gaucher and late-onset Tay-Sachs disproportionately afflict Ashkenazic Jews.

Dr. Edwin Kolodny of New York University, who conducted one of the studies (the other was at Case Western Reserve University), was quick to emphasize that anecdotal evidence was far more promising. “Most of the patients who began the trial, and almost all the patients who remained at the end of the trial, want to continue taking the drug,” he said. “That means to me that they appreciate some positive benefits.”

Such benefits include improvement in speech patterns and articulation, reduction in psychotic episodes and general mental stabilization.

However, the hope was that Zavesca would stop or at least slow the decrease in muscle strength characteristic of such progressive neurodegenerative diseases as Tay-Sachs. “The data did not confirm that,” Kolodny said.

According to Kolodny, there are two other potential routes to treatment of late-onset Tay-Sachs. At least one biotechnology company, Genzyme, is developing a substrate synthesis inhibitor — the same type of drug as Zavesca — that would block production of the lipid that builds up in nerve cells of Tay-Sachs patients. It may soon be used in human trials.

The second option, known as the “chaperone molecule approach,” is currently in development. Here, doctors produce a small molecule in Tay-Sachs patients that can help correct the faulty hexosaminidase A enzyme.

Meanwhile, the jury is still out on trials currently being conducted for the use of Zavesca to treat juvenile and infantile (early-onset) Tay-Sachs. “The hope is that maybe in children and infants [Zavesca] is metabolized differently, and has an impact on the disease,” Crawford said.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse..

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.